Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PERINDOPRIL: THE POSSIBILITY OF ANTIHYPERTENSIVE AND RENOPROTECTIVE THERAPY

https://doi.org/10.20996/1819-6446-2011-7-4-501-506

Full Text:

Abstract

Blood pressure (BP) control in patients with chronic kidney disease is one of the most pressing problems in modern cardiology and nephrology. Perindopril therapy reduces cardiovascular risk in patients with arterial hypertension and nephropathy, provides adequate BP control and target organs protection.

 

About the Authors

O. V. Dralova
I.M. Setchenov First Moscow State Medical University.
Russian Federation


M. L. Maksimov
I.M. Setchenov First Moscow State Medical University.
Russian Federation


References

1. Kobalava Zh.D., Efremovtseva M.A. Combination antihypertensive therapy in patients with hypertension and chronic nephropathy. Serdtse 2005; 3: 138–140. Russian (Кобалава Ж.Д., Ефремовцева М.А. Комбинированная антигипертензивная терапия у пациентов с АГ и хронической нефропатией. Сердце 2005;3:138–140).

2. Tereshchenko S.N., Demidova I.V. Renal function in chronic heart failure in patients with elderly. Serdtse 2002; 5: 251–258. Russian (Терещенко С.Н., Демидова И.В. Почечная функция при хронической сердечной недостаточности у больных пожилого и старческого возраста. Сердце 2002;5: 251–258).

3. K/DOQ1 clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5Suppl 1): SI—290.

4. Peterson J.C., Adler S., Burkart J. et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995;123: 754-62.

5. Penegrer T.V., Klag M.J., Feldman H.I. et al. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 1993;269: 1272–7.

6. Martinez M., Moreno A., Aguirre A. et al. Frequency and determinants of mi-croalbuminuria in mild hypertension: a primary-care-based study. J Hypertension 2001;19:319–26.

7. Koboti H., Nangaku M., Navar G. et al. The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. Pharmacol Rev. 2007;59(3):251–287.

8. Navar L.G., Inscho E.W., Majid S.A. et al. Paracrine regulation of the renal mi-crocirculation. Physiol Rev. 1996. - 76:425–536.

9. Paul M., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems. Phys-iol Rev. 2006. - 86:747–803.

10. Timmermans P.B., Wong P.C., Chiu A.T. et al. Angiotensin II receptors and an-giotensin II receptor antagonists. Pharmacol Rev. 1993. - 45:205–251.

11. Navar L.G., Harrison-Bernard L.M., Imig J.D. et al. Renal responses to AT1 receptor blockade. Am J Hypertens. 2000; 13:45S–54S.

12. Zhuo J., Moeller I., Jenkins T. et al. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998;16: 2027-37.

13. Matsusaka T., Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997;59: 395-412.

14. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol Dial Transplant 1999; 14; Suppl 1: 42-44.

15. Tomilina N.A., Bagdasaryan A.R. The mechanisms and pharmacological inhibition of nephrosclerosis intrarenal renin-angiotensin system as the basis renoprotective strategies for chronic diseases of native kidneys and renal transplant. Nefrologiya i dializ 2004; 3 (6): 226-234. Russian (Томилина Н.А., Багдасарян А.Р. Механизмы нефросклероза и фармакологическая ингибиция внутри почечной ренин-ангиотензиновой системы как основа нефропротективной стратегии при хронических заболеваниях нативных почек и почечного трансплантата. Нефрология и диализ 2004; 3 (6): 226-234).

16. Shestakova M.V. The modern possibilities of the renoprotection at hypertension and diabetes. Serdtse 2004; 1: 23–25. Russian (Шестакова М.В. Современные возможности нефропротекции при артериальной гипертензии и сахарином диабете. Сердце 2004; 1: 23–25).

17. Nikolaev A.N. Progression of renal failure: Participation of the ATI-receptor. Russkiy meditsinskiy zhurnal 2001; 24: 1136- 1137. Russian (Николаев А.Н. Прогрессирование почечной недостаточности : Участие ATI-рецептора. Русский медицинский журнал 2001; 24: 1136- 1137).

18. Hall A.S. Ace inhibition and target organ protection 1998; Hoechst Marion Roussel. Chapter 7.

19. Nishijama K., Igari T., Nanda S., Ishii M. Long-term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients. Am J Hypertens 1991; 4: 52S-3S.

20. Matsuda H., Hayashi K., Wakino S. et al. Role of endothelium-derived hyper-polarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension. 2004;43(3):603-609.

21. Storzhakov G.I., Tomilina N.A, Shilo V.Yu. et al. The congestive heart failure in patients with the chronic renal failure. Serdechnaya nedostatochnost' 2005; 3: 100–104. Russian (Сторжаков Г.И., Томилина Н.А, Шило В.Ю. и др. Сердечная недостаточность у больных с хронической почечной недостаточностью. Сердечная недостаточность 2005; 3: 100–104).

22. Dedov I.I., Shestakova M.N. The diabetic nephropathy. Moscow: Universum Pablishing; 2000. Russian (Дедов И.И., Шестакова М.Н. Диабетическая нефропатия. М.: Универсум Паблишинг, 2000).

23. Levey A.S., Coresh J., Balk E. et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139: 137–147.

24. Konradi A.O. Rational choice of an ACE inhibitor, from the standpoint of the renoprotection. Arterial'naya gipertenziya 2004; 10:177–180. Russian (Конради А.О. Рациональный выбор ингибитора АПФ с позиций нефропротекции. Артериальная гипертензия 2004; 10:177–180).

25. Podzolkov V.I. Antihypertensive therapy and the concept of the renoprotection. Serdtse 2003; 3: 128–131. Russian (Подзолков В.И. Антигипертензивная терапия и концепция нефропротекции. Сердце 2003; 3: 128–131).

26. Lewis E.J. Hunsicker L.G., Bain R.P. et al. The effect of ACE inhibition on diabetic nephropathy. N Eng J Med 1993; 329:1456–62.

27. Viberti G.C., Mogenson C.E., Groop L.C. et al. Effects of captopril on progression of clinical proteinuria in patients with insulin–dependent diabetes mellitus. JAMA 1994; 271: 275–9.

28. Laffel L.M.B., McGill B., Gans D.G. et al. The beneficial effect of ACE with cap-topril on diabetic nephropathy in patients with type 1 diabetes mellitus. Am J Мed 1995; 99:497–504.

29. Ravid M., Lang R., Rachmani R. et al. Long–term renoprotective effect of ACE inhibition in non–insulin–dependent diabetes mellitus. Arch Intern Med 1996; 156:286–289.

30. Lebovitz H.E., Weigrmann Т.В., Сnааn А. et al. Renal protective effects of enalapril in hypertensive NISSM: role of baseline albuminuria. Kidney Int 45: SI 50–SI 55.

31. Ostroumova O.D., Golovina O.V., Rolik N.L. The organoprotective effect of an-tihypertensive drugs: Does it matter in clinical practice? Consilium medicum 2004; 6: 344–349. Russian (Остроумова О.Д., Головина О.В., Ролик Н.Л. Органопротективный эффект антигипертензивных препаратов: имеет ли это значение для клинической практики? Consilium medicum 2004; 6: 344–349).

32. Giatras I., Lau J., Levey A.S. Effect of angiotensin–converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta–analysis of random-ized trials. Ann Intern Med 1997;127:337—45.

33. Konradi A.O. The combination antihypertensive therapy in patients with diabetes. Serdtse 2005; 3:128–131. Russian (Конради А.О. Комбинированная антигипертензивная терапия у больных с сахарным диабетом. Сердце 2005; 3:128–131).

34. Ruilope L.M., Alcazar J.M., Hernandez E. et al. Long-term influence of anti-hypertensive therapy on microalbuminuria in essential hypertension Kydney Int 1994; 45: 171–3.

35. Cansevoort R.T., Sluiter W.L., Hemmelder M.G. et al. Antiproteiuretic effect of blood pressure lowering agents: a meta-analysis of clinical trials. Nephrol Dial Transplant 1995; 10: 1963–74.

36. Baguet J.P., Robitail S., Boyer L. et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005; 5 (2): 131–40.

37. National guidelines for diagnosis and treatment of hypertension. The Experts Committee of RMSAH and RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) suppl 2:1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Комитет экспертов РМОАГ и ВНОК. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2:1-32).

38. Ivanov D.D. Microalbuminuria: a look of nephrologist. Zdorov'e Ukrainy 2008; 21/1: 18-19. Russian (Иванов Д.Д. Микроальбуминурия: взгляд нефролога. Здоровье Украины 2008; 21/1:18-19).

39. Remme W.J., Deckers J.W., Fox K.M. et al. EUROPA Investigators. Secondery prevention of coronary disease with ACE inhibition-does blood pressure reduction with perindopril explain the benefits in EUROPA ? CardovascDrugs Ther 2008; 23:161-170.

40. Ceconi C., Francolini G., Olivares A. et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Parmacol 2007;577:1—6.

41. Ceconi C., Francolini G., Bastianon D. et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis in vivo and in vivo studies. Cardovasc Drugs Ther 2007;21:423—429.

42. Marre M., Fernandez M., Garcia-Puig J., et al., Value of natrilix SR hypertensive type 2 diabetic patients with microalbuminuria J. Hypertens. 2002; 20 (4): 338.

43. Heerspink H.J., Ninomiya T., Perkovic V. et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31(23):2888-96.

44. Perkovic V., Ninomiya T., Arima H. et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol. 2007;18(10):2766-72

45. Bots M.L., Remme W.J., Lüscher T.F. et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther. 2007 ;21(4): 269-279

46. Ceconi C., Francolini G., Bastianon D. et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther. 2007;21(6):423-429.

47. ADVANCE Collaborative Group. Rationale and design of the ADVANCE Study: a Randomized trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 Diabetes mellitus. J. Hypertens. 2001; 19,4: S21–S28.

48. Danhlof B., Gosse P. on behalf of the PICXEL investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 11: 2063–70.

49. Mourad J.J., Le Jeune S. Evaluation of high dose of perindopril/indapamide combination in reducing blood pressure and improving end-organ protection in hypertensive patients. Current medical research and opinion 2009; 25: 2271–80.

50. Mogensen C.E. et al. Effect of a low dose Perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71.

51. PROGRESS collaborative group. Randomized trial of perindopril based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358:1033–41.

52. Mourad J.J., Vaisse B., Lopez-Sublet M. et al. What rates of blood pressure normalisation can be expected from a first-line combination therapy in the real life? The OPTIMAX study. Eur Heart J 2006; 27(suppl): 298. Abstract 1792.

53. Jarh D.M., Barbič-Žagar B., Grošelj M. Perindopril — a landmark in hypertension and cardiovascular disease management. Kardio list 2011;6(3-4):56-59.

54. Final report. Postmarketing surveillance study of efficacy and safety of perindopril (Prenessa®) in the treatment of mild to moderate arterial hypertension. Data on file. Krka d. d., Novo mesto, Slovenia, 2007.


For citation:


Dralova O.V., Maksimov M.L. PERINDOPRIL: THE POSSIBILITY OF ANTIHYPERTENSIVE AND RENOPROTECTIVE THERAPY. Rational Pharmacotherapy in Cardiology. 2011;7(4):501-506. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-4-501-506

Views: 832


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)